News Release

HemogloBind™ is Cited to Remove Hemolysis Interference in A Point-Of-Care Electrochemical Biosensor for Biomarkers of LPS-induced Sepsis

MONMOUTH JUNCTION, NJ, March 28, 2024 -- Biotech Support Group reports on a journal article describing the simplicity and efficiency of HemogloBind™, to remove Hemoglobin interference prior to a point-of-care (POC) electrochemical biosensor for sepsis biomarkers.

The citation is:

Neil Adrian P. Ondevilla, Peng-Wen Liu, Wan-Ting Huang, Tzu-Ping Weng, Nan-Yao Lee, Syu-Cing Ma, Jian-Jang Huang, Tak-Wah Wong, Hsien-Chang Chang, A point-of-care electrochemical biosensor for the rapid and sensitive detection of biomarkers in murine models with LPS-induced sepsis, Biosensors and Bioelectronics, Volume 254, 2024, 116202, ISSN 0956-5663, https://doi.org/10.1016/j.bios.2024.116202.

Sepsis is a life-threatening condition, which is irreversible if diagnosis and intervention are delayed. The response of the immune cells towards an infection triggers widespread inflammation through the production of cytokines, which may result in multiple organ dysfunction and eventual death. Conventional detection techniques fail to provide a rapid diagnosis because of their limited sensitivity and tedious protocol. This study proposes a point-of-care (POC) electrochemical biosensor that overcomes the limitations of current biosensing technologies in the clinical setting by its integration with electrokinetics, enhancing the sensitivity to picogram level compared with the nanogram limit of current diagnostic technologies. Tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and microRNA-155 (miR-155) were monitored in a lipopolysaccharide (LPS)-induced septic mouse model.

The article states “To mimic the clinical scenario of sepsis, LPS was injected in mice and the serum was extracted in accordance with the experimental methodology. Hemolysis is common in blood samples, which can interfere with the detection. Prior to the analysis, the hemolyzed samples were pretreated for 15 min with Hemoglobind™ (Biotech Support Group LLC, NJ). The hemoglobin-depleted serum samples were drop-cast onto the surface of the modified strip electrodes followed by the subsequent electrokinetic concentration and electrochemical detection.”. The authors conclude that the novel POC electrochemical platform promotes the hybridization of trace amounts of biomarkers within 60 s with the completion of the overall detection procedure within 5 and 20 min for non-hemolyzed and hemolyzed samples, respectively, which can greatly address the current limitations in the clinical setting. Serum levels of TNF-α, IL-6, and miR-155 in the picogram range provide an early prediction for the severity of infection.

“I am pleased to see that the use of HemogloBind™ was necessary to remove the interference from Hemoglobin so efficiently. As the analytes evaluated were in the pigogram range, this article demonstrates the unique selectivity and efficiency that HemogloBind™ can provide, potentially in a clinical setting.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Click here for more information on HemogloBind™

Click here for more information on all of our Hemoglobin Removal products

Keywords: Hemoglobin depletion, HemogloBind™, Electrochemical biosensor,

DC-Biased AC electrokinetics, sepsis, cytokines, miR-155, Tumor necrosis factor-alpha alpha (TNF-α), interleukin-6 (IL-6), Point-of-care, POC

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for expanding proteomic analysis. Following a tiered business strategy, the company continues its growth in the consumable research products area. For this market, key products include: AlbuVoid™ and AlbuSorb™ PLUS for albumin & IgG depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for low abundance and family specific proteome enrichment. For more information, go to http://www.biotechsupportgroup.com

For business development contact: Matthew Kuruc
732-274-2866 mkuruc@biotechsupportgroup.com